# PLOS ONE

# Increased serum resistin but not G-CSF levels are associated in the pathophysiology of major depressive disorder: Findings from a case-control study

Smaranika Rahman[1☉], Amena Alam Shanta[1☉], Sohel Daria[1], Zabun Nahar[1], Mohammad Shahriar[1], MMA Shalahuddin Qusar[2], Sardar Mohammad Ashraful Islam[1], Mohiuddin Ahmed Bhuiyan[1], Md. Rabiul Islam[1]*

1 Department of Pharmacy, University of Asia Pacific, Farmgate, Dhaka, Bangladesh, 2 Department of Psychiatry, Bangabandhu Sheikh Mujib Medical University, Shahabagh, Dhaka, Bangladesh

☉ These authors contributed equally to this work.
* robi.ayaan@gmail.com

## Abstract

### Background

Many studies have predicted major depressive disorder (MDD) as the leading cause of global health by 2030 due to its high prevalence, disability, and illness. However, the actual pathophysiological mechanism behind depression is unknown. Scientists consider alterations in cytokines might be tools for understanding the pathogenesis and treatment of MDD. Several past studies on several inflammatory cytokine expressions in MDD reveal that an inflammatory process is activated, although the precise causes of that changes in cytokine levels are unclear. Therefore, we aimed to investigate resistin and G-CSF in MDD patients and controls to explore their role in the pathogenesis and development of depression.

### Methods

We included 220 participants in this study. Among them, 108 MDD patients and 112 age-sex matched healthy control (HCs). We used DSM-5 to evaluate study participants. Also, we applied the Ham-D rating scale to assess the severity of patients. Serum resistin and G-CSF levels were measured using ELISA kits (BosterBio, USA).

### Results

The present study observed increased serum resistin levels in MDD patients compared to HCs (13.82 ± 1.24ng/mL and 6.35 ± 0.51ng/mL, p <0.001). However, we did not find such changes for serum G-CSF levels between the groups. Ham-D scores showed a significant correlation with serum resistin levels but not G-CSF levels in the patient group. Furthermore, ROC analysis showed a fairly predictive performance of serum resistin levels in major depression (AUC = 0.746).

## Conclusion

The present study findings suggest higher serum resistin levels are associated with the pathophysiology of MDD. This elevated serum resistin level may serve as an early risk assessment indicator for MDD. However, the role of serum G-CSF in the development of MDD is still unclear despite its neuroprotective and anti-inflammatory effects.

## Introduction

Major depressive disorder (MDD) is a complex and devastating mental health disorder across the world. Depressive people experience anhedonia in which they do not find peace in activities that were pleasurable once; usually characterized by the persistent occurrence of depressed mood, low self-esteem, worse sleep or appetite, and even thought of suicide or death [1]. Clinicians define major depression as when the depressive symptoms accompanied by other physical changes last for at least two weeks. These changes include psychomotor retardation or agitation, alteration in appetite, body weight, sleep pattern, and sustained fatigue depending on the severity and number of episodes [2]. The WHO has classified MDD as the third largest cause of disease burden since 2008. The authority expects depression to be the leading cause of global disease by 2030 [3]. Worldwide, about 280 million people suffer from depression, and women are more susceptible to developing depressive symptoms than men [4]. Approximately 20% of the adult population worldwide may experience depressive episodes at some point in their lives, and about 80% of MDD patients may have at least one more episode [5,6]. Depression is often incorrectly diagnosed or misdiagnosed due to a lack of recourses, skilled healthcare practitioners, and social stigma associated with mental disorders [4]. However, the most significant impediments to the successful management of depression are the lack of appropriate quantitative early risk assessment markers and inaccurate measurements. MDD is currently diagnosed mostly through clinical examination, patient self-report, and subjective evaluation of depressed symptoms [7].

MDD is a multifaceted, multi-etiological, unpredictable disease condition with a variety of symptoms. There is no single reason behind the onset of depression. A complex interaction among genetic, biochemical, nutritional, environmental, and psychological variables causes depression [8–13]. However, the pathophysiology of MDD is still inconclusive. Several hypotheses are potentially associated with the pathophysiology of MDD. Among them, cytokine alterations [14], inflammatory responses [15], the hypothalamic-pituitary-adrenal (HPA) axis activation [12], serotonin mechanism [16], catecholamine synthesis [17], and neurotrophic actions [18] are noticeable. Cytokines are proteins in nature, and immune cells secrete them. Therefore, they can cause local and systemic immune responses and induce inflammation [14]. The activated microglia produce pro-inflammatory cytokines during inflammation. These increased cytokine levels hyperactivate the HPA axis. Therefore, cortisol, adrenocorticotropic hormone, and corticotrophin-releasing hormone levels increase in the human body [19]. They also boost the activity of the 2-indoleamine, 3-dioxygenase enzymes. Altogether they cause neurodegeneration and ultimately MDD development [20].

Resistin is a pro-inflammatory adipocytokine [21]. Inflammatory cells such as macrophages can produce it [22]. It can cause the expression of many cytokines in the human body [23–25]. Cytokine expression inhibits the synthesis of dopamine and noradrenaline in the central nervous system by the hypothalamus. Therefore, reduced intra-synaptic monoamine levels may develop depressive symptoms [26–28]. However, G-CSF involves in pro-and anti-inflammatory actions [29–31]. The neuroprotective properties of G-CSF receptors can show anti-

inflammatory effects on dopaminergic neurons during the neurodegenerative process in the brain [32–35]. Many studies have revealed increased serum resistin and G-CSF levels in MDD patients [36,37]. But Papacostas et al. reported that serum resistin levels decreased in patients suffering from depression. Also, they did not notice any significant change in serum resistin levels between MDD and healthy controls (HCs) in their replication studies [28]. However, some other studies have failed to show significant changes in the serum levels of resistin and G-CSF in MDD patients compared to HC [38,39]. Therefore, the therapeutic significance of the relationship between serum resistin and G-CSF levels with depression is still unclear. Thus, we aimed to evaluate the serum resistin and G-CSF of MDD patients in a case-control study to find their relationship with the pathogenesis of depression.

## Materials and methods

### Study population

We thought the exposed percentage and alpha risk as 10% and 5%, respectively. Also, we considered 90% statistical power and an odds ratio of 2 for this 1:1 matched case-control study. According to the above estimates, the hypothetical sample size was 252 (126 MDD patients and 126 HCs). Therefore, we included 108 MDD patients and 116 HCs from the native Bangladeshi population. We recruited MDD patients from a tertiary care teaching hospital in the capital city of Bangladesh. Before participation, we obtained informed consent from each participant of the study. A psychiatrist assessed MDD patients based on the DSM-5 criteria for this study. We recruited age-sex matched HCs from different parts of the capital city in Bangladesh. We interviewed all the study participants using the same structured questionnaire to rule out any previous or current psychotic condition defined by the DSM-5. Also, we applied the Ham-D rating scale to assess the severity of MDD patients suffering from depression. We included depressive patients who had a Ham-D score of seven or higher. This study excluded subjects from the present study who had other comorbid mental health disorders. Also, we considered cardiovascular diseases, renal or liver disorders, excessive obesity, abnormal body mass index (BMI), autoimmune diseases, infectious diseases, uncontrolled endocrine diseases as additional exclusion criteria for this study participants. This study also excluded participants who were addicted to alcohol or other substances abuse. The socio-demographic characteristics of both patients and healthy individuals such as height, weight, and BMI were examined and recorded appropriately using a predesigned questionnaire. We performed all investigations following the principle described in the declaration of Helsinki, Seoul, Korea, version 2008.

### Blood sample collection

We collected a 5ml blood sample from the cephalic vein of each participant. We placed the collected blood sample in a falcon tube and allowed it for coagulation for half an hour at room temperature. Then, the coagulated blood samples were centrifuged at 3000rpm for 15 minutes. We collected transparent serum samples from the upper part of falcon tubes. Finally, the serum samples were aliquoted into the polypropylene tube and preserved at -80˚C until further investigation.

### Measurement of serum cytokine levels

We measured serum resistin and G-CSF levels using ELISA kits following the instructions supplied by the kit manufacturer (BosterBio, USA). At first, we placed 100μl of sample and standard solutions into the appropriate wells in a 96-well microtiter plate. We incubated the plate for two hours at room temperature. Then we removed the liquid from the wells. A 100μl of the

biotinylated anti-human antibody of each cytokine was added to the corresponding wells and mixed thoroughly. We sealed the plates again and incubated them for another 60 minutes at 37˚C temperature. After this incubation, we aspirated the contents and wells rinsed three times with 300μl of wash buffer. Then we added 100μl of the avidin-biotin-peroxidase complex into the wells and incubated at 37˚C temperature for another 30 minutes. After aspirating the contents of each well once more, we rinsed them five times with 300μl of wash buffer. We incubated the plates again at room temperature for half an hour in the dark place after adding 90μl of the color development reagent. After this incubation, we added 100μl stop solution into each well to stop the reaction process. We measured the absorbance at 450 nm within 30 minutes after stopping the reaction. We calculated serum resistin and G-CSF levels as pg/mL. The minimum detection value for serum resistin and G-CSF were <1pg/ml and <0.5pg/ml, respectively. The researcher team who conducted the assays was blind to the identities of the sample or any clinical data. Additionally, we performed all assays by the same research team to avoid interpersonal heterogeneity in the study results of measured cytokines.

## Statistical analysis

We used Microsoft excel 2016 and SPSS software (version 25) for data processing and analysis. Independent sample t-tests and Pearson's correlation coefficient test were used to compare the study parameters between MDD patients and HCs. Also, we applied Fisher's exact test for categorical variables. Pearson correlation coefficient test was used to find the association between laboratory findings and Ham-D scores among MDD patients. We used boxplot graphs to show the changes in serum cytokine levels in MDD patients and HCs. In the patient group, we used scatter plot graphs to illustrate associations of serum levels of resistin and G-CSF with Ham-D scores. Also, we performed ROC curve analysis to predict the diagnostic performance of altered cytokine in major depression. We presented the data as mean values±standard error of the mean (SEM). We considered significant results from the statistical analyses if the p-values indicated as 0.05 or lower.

## Ethics

The ethical review committee of Bangabandhu Sheikh Mujib Medical University approved the research protocol (No. BSMMU/2019/3507). We briefed about the objective of this study to all participants and obtained written consent from them. We performed all investigations following the Declaration of Helsinki.

## Result

### Sociodemographic profiles of the study population

We categorized all the participants in this study according to their biophysical features and sociodemographic profiles (Table 1).

Both cases and controls were similar in terms of their age (MDD patients: 32.15±0.88 years, HCs: 33.67±0.89 years; p = 0.226), BMI (MDD patients: 25.03±0.46 kg/m$^2$, HCs: 24.85±0.38 kg/m$^2$; p = 0.761), and smoking history (MDD patients/HCs: 34.25%/33.04%; p = 0.848). Participants with female sex were higher in MDD patients and HCs than males. The majority portion of the study population were nonsmokers and belonging to the medium economic class. We noticed a significant portion of MDD patients were young adults (50.00%). More than half of the participants had a normal BMI. Rural people with a medium-income range had a more propensity to have depression than others. Unemployment may be a reason to develop MDD because we observed 47.22% of MDD patients were unemployed.

**Table 1. Socio-demographic characteristics of the study population.**

| Characteristics | MDD patients (n = 108) Mean ± SEM | Healthy controls (n = 112) Mean ± SEM | *P value* |
|---|---|---|---|
| Age in years | 32.15± 0.88 | 33.67± 0.89 | 0.226 |
|   18–30 | 54 (50.00%) | 54 (48.22%) | |
|   31–45 | 45 (41.67%) | 39 (34.82%) | |
|   46–60 | 9 (8.33%) | 19 (16.96%) | |
| Sex | | | 0.513 |
|   Male | 52 (48.15%) | 49 (43.75%) | |
|   Female | 56 (51.85%) | 63 (56.25%) | |
| Marital Status | | | 0.115 |
|   Married | 63 (58.33%) | 71 (63.39%) | |
|   Unmarried | 45 (41.67%) | 41 (36.61%) | |
| BMI (kg/m$^2$) | 25.03 ± 0.46 | 24.85 ± 0.38 | 0.761 |
|   Below 18.5 (CED) | 3 (2.78%) | 2 (1.79%) | |
|   18.5–25 (normal) | 62 (57.41%) | 60 (53.57%) | |
|   Above 25 (obese) | 43 (39.81%) | 50 (44.64%) | |
| Education level | | | < 0.001 |
|   No formal education | 13 (12.04%) | 11 (9.82%) | |
|   Primary level | 16 (14.82%) | 11 (9.82%) | |
|   Secondary level | 31 (28.70%) | 22 (19.64%) | |
|   Higher Secondary level | 21 (19.44%) | 25 (22.32%) | |
|   Graduate and above | 27 (25%) | 43 (38.40%) | |
| Family income (KBDT)/month | 69.38 ± 3.58 | 77.90± 9.79 | 0.415 |
|   Below 40 | 30 (27.78%) | 28 (25%) | |
|   40–100 | 59 (54.63%) | 63 (56.25%) | |
|   Above 100 | 19 (17.59%) | 21 (18.75%) | |
| Job status | | | 0.001 |
|   Business | 6 (5.56%) | 17 (15.18%) | |
|   Service | 18 (16.66%) | 8 (7.14%) | |
|   Unemployed | 51 (47.22%) | 36 (32.14%) | |
|   Student | 6 (5.56%) | 20 (17.86%) | |
|   Others | 27 (25%) | 31 (27.68%) | |
| Economic class | | | 0.892 |
|   Low | 30 (27.78%) | 28 (25%) | |
|   Medium | 59 (54.63%) | 63 (56.25%) | |
|   High | 19 (17.59%) | 21 (18.75%) | |
| Smoking habit | | | 0.848 |
|   Yes | 37 (34.25%) | 37 (33.04%) | |
|   No | 71 (65.75%) | 75 (66.96%) | |
| Residence area | | | 0.001 |
|   Rural | 63 (58.33%) | 42 (37.50%) | |
|   Urban | 45 (41.67%) | 70 (62.50%) | |

Abbreviations: BMI, body mass index; CED, chronic energy deficiency; KBDT, kilo Bangladeshi taka; MDD, major depressive disorder; SEM, standard error mean.

## Clinical outcome and laboratory findings

We presented clinical features and laboratory results of the study population in Table 2 and Fig 1. Ham-D scores of MDD patients and HCs were 23.37±0.41 and 5.20±0.31, respectively (p<0.001). Also, DSM-5 scores of MDD patients and HCs were 7.06±0.15 and 1.85±0.16,

**Table 2. Clinical information and laboratory findings of the study population.**

| Parameters | MDD patients (n = 108) Mean ± SEM | Healthy controls (n = 112) Mean ± SEM | *p value* |
|---|---|---|---|
| DSM-5 score | 7.06± 0.15 | 1.85± 0.16 | < 0.001 |
| Ham-D score | 23.37± 0.41 | 5.20 ± 0.31 | < 0.001 |
| Serum resistin level (ng/mL) | 13.82± 1.24 | 6.35± 0.51 | < 0.001 |
| In male (P/C:52/49) | 15.05 ± 2.01 | 6.06 ± 0.79 | < 0.001 |
| In female (P/C:56/63) | 12.68 ±1.50 | 6.57 ± 0.68 | < 0.001 |
| Serum G-CSF level (pg/mL) | 55.45 ± 7.20 | 51.39± 5.89 | 0.660 |
| In male (P/C:52/49) | 64.62 ± 11.33 | 63.92 ± 10.89 | 0.965 |
| In female (P/C:56/63) | 46.93± 8.99 | 41.64± 5.63 | 0.611 |

Abbreviations: DSM-5, diagnostic and statistical manual for mental disorders, 5th edition; Ham-D, 17-item Hamilton depression rating scale; G-CSF, granulocyte-colony stimulating factor; MDD, major depressive disorder; P/C, patients and control; SEM, standard error mean.

respectively (p<0.001). We observed higher serum resistin levels in MDD patients (13.82 ±1.24ng/mL) than HCs (6.35±0.51ng/mL). However, we did not observe significant difference in serum G-CSF concentrations between the groups (MDD patients: 55.45±7.20pg/mL; HCs: 51.39±5.89pg/mL; p = 0.660). Moreover, we observed significantly higher levels of serum resistin in both male (15.05±2.01ng/mL) and female (12.68±1.50ng/mL) MDD patients than male (6.06±0.79ng/mL) and female (6.57±0.68ng/mL) in HCs, respectively (Table 2).

In the case of G-CSF, there were no significant changes between the subgroups (male MDD patients and HCs: 64.62±11.33pg/mL and 63.92±10.89pg/mL, respectively, p = 0.965; female MDD patients and HCs: 46.93±8.99pg/mL and 41.64±5.63pg/mL, respectively, p = 0.611).

## Association between clinical outcome and lab findings

Pearson's correlation test established the association between serum resistin levels and Ham-D scores among MDD patients. We observed a significant positive correlation between serum resistin levels and Ham-D scores in MDD patients (r = 0.513, p<0.001). However, we did not find any positive or negative correlations between serum G-CSF levels and Ham-D scores in the patient group. According to sex-specific scatter plot graphs, we noticed female MDD



**Fig 1. Distribution of serum inflammatory cytokine levels in MDD patients and healthy controls.** Boxplot graphs showing the median, maximum and minimum value range.

**Fig 2. Scatter plot graphs showing association and mean difference of serum resistin levels with Ham-D scores of study participants.** a: Patient and control specific association, b: Sex specific association among MDD patients.

patients with higher Ham-D scores had elevated serum resistin levels (Fig 2). Again, we did not find such correlations between serum G-CSF levels and Ham-D scores in MDD patients. Also, the ROC curve analysis of serum resistin showed moderate sensitivity and specificity as 65% and 67%, respectively (Fig 3). Moreover, findings from ROC analysis showed the positive prospective value (PPV) and negative prospective value (NPV) as 63% and 62%, respectively. In that case, we detected the cut-off value for serum resistin as 6.39 ng/mL and the area under the curve (AUC) as 0.746. Moreover, we presented the summary of the present study by Fig 4.

## Discussion

The established quantitative diagnostic tests for major depression are still absent. The reason behind the unavailability of laboratory parameters for the diagnosis of depression might be due to insufficient sensitivity and specificity of individual diagnostic markers. The present study investigated serum-based cytokine markers resistin and G-CSF in MDD patients compared to HCs. Here we found elevated serum resistin levels in MDD patients than HCs. We also found a positive correlation between serum resistin levels and Ham-D scores in the patient group. However, serum G-CSF levels did not alter significantly in depression. Also, we found no significant association between serum G-CSF levels and Ham-D scores in MDD patients.

Resistin and G-CSF are inflammatory cytokines, and the actual pathophysiology of these cytokines in the pathogenesis of depression is still elusive. But activation of cytokine receptors in neurons [40], amplified expression of serotonin transporters [41], activation of the kynurenine pathway [42], decreased neuronal growth factors [43], and the stimulation of the HPA axis [44] are possible mechanisms linking cytokine-mediated immune stimulation to the pathogenesis of depression. Moreover, alterations in neurotransmitter synthesis, release, and reuptake can support the above pathophysiological mechanism [45]. Resistin is a pro-inflammatory cytokine produced by adipose tissue that might contribute to insulin resistance in humans [46]. According to some previous study findings, resistin can play its effect on insulin compassion may be mediated via its capability to stimulate the synthesis of anti-inflammatory cytokines (i.e., TNF-α, IL-6) [27,47,48]. A higher level of resistin possesses depressive episodes in MDD as it stimulates the synthesis of anti-inflammatory cytokines such as TNF-α and ketamine [49,50]. However, resistin inhibits dopamine and noradrenaline release in the brain

**Fig 3. Receiver operating characteristic (ROC) curve for serum resistin.** The cut-off point was detected as 6.39 ng/mL.

https://doi.org/10.1371/journal.pone.0264404.g003

through the hypothalamus. Thus, it can lower the level of intrasynaptic monoamine. Therefore, it can help to develop depressive symptoms in individuals [28]. The research found a positive correlation between circulating levels of resistin and free cortisol concentrations in MDD patients. This association shows that increased serum cortisol is responsible for developing depressive symptoms [9,36]. The finding of the present study is consistent with some previous studies. A study found that serum resistin levels in MDD patients were high before treatment and remained unchanged in individuals whose condition had not improved after antidepressant therapy [36]. Another study found a higher level of resistin in depression. Also, they

**Fig 4. Summary of the study with procedures and findings.**

https://doi.org/10.1371/journal.pone.0264404.g004

observed a significant drop in serum resistin levels in patients who had an antidepressant response to ketamine [51]. However, Archer et al. found that women with MDD had greater resistin levels at baseline that did not differ after antidepressant treatment [52]. Jentsch et al. reported higher serum and urine resistin levels in MDD patients. Also, they identified these elevations were more in females than males in a recent gender-specific investigation [53]. Also, another study discovered a positive association between resistin levels and atypical depressive symptoms. However, they did not find any correlations between the typical depressive characteristics and serum resistin levels in MDD patients [21]. Many earlier studies supported their findings [22,27,54–57].

Serum G-CSF levels might involve in the neuroinflammatory process and influence the development of depression. It can also influence leukocyte mobilization from the bone marrow. Therefore, thus increases the production of cytokines [58]. G-CSF helps the propagation and diversity of myeloid progenitors. G-CSF helps the production of granulocyte precursors and inhibition of apoptosis [59,60]. Moreover, G-CSF shows anti-inflammatory and neuroprotective actions in neurodegenerative disorders through dopaminergic neurons in the CNS [29,30]. Therefore, scientists consider G-CSF as a potential medication for neurological diseases [30]. Inconsistent with the present study findings, Lehto et al. did not find any alterations of G-CSF levels in MDD patients compared to HCs [61]. Also, Einvik et al. did not find any significant association between serum level of G-CSF and depression [39]. A recent study

found an inverse relationship between serum G-CSF levels and age in substance use disorder (SUD) compared to HCs [62]. However, Dahl et al. revealed that plasma G-CSF levels became normalized during the recovery phase of depressive episodes in MDD patients [63]. Therefore, we can anticipate that G-CSF might have anti-inflammatory and antidepressant actions based on the above findings [63].

The ROC curve analysis of serum resistin is another strong point of the present study. AUC of ROC analysis was fair (0.746) for serum resisting in depression (p<0.001). Some previous studies measured serum resistin levels in depression, but their results were not robust to evaluate the risk of developing depression due to its low prognostic performance [21,36]. Findings from the ROC analysis showed the sensitivity, specificity, PPV, NPV of serum resistin in MDD patients as 65%, 67%, 63%, and 62% for IL-7, respectively. Similar to the present findings, a longitudinal study reported resistin's association with depressive symptoms. That association was longitudinal, multiply adjusted, and showed a specific mediation of depression's association with cognitive impairment. However, the same study found no association of serum G-CSF with depression [64]. Moreover, major depression is a multifactorial condition accompanied by genetic and environmental features [65]. Therefore, it is vital to define any biological factors precisely that involved might involve in depression. The results of the present investigation showed an increase in serum resistin levels in MDD without a substantial change in G-CSF levels is intriguing.

The present study found elevated serum resistin levels in MDD patients than HCs, but serum G-CSF levels did not alter significantly in depression. Moreover, a positive correlation between serum resistin levels and Ham-D scores in the patient group has been found, but no significant correlation between serum G-CSF levels and Ham-D scores in MDD patients has been established. The findings from the present study might be more complicated than presumed and could vary based on individual MDD patients' characteristics. Therefore, the findings from the study should be considered as preliminary; a new study with a large, homogenous population and by controlling other confounding factors should be conducted in a similar setting to obtain better results. The predictive performance of serum resistin was found fair (0.746) by ROC curve analysis that might be helpful in the management of major depression. Serum resistin might be used to evaluate the risk of developing depression applying the prognostic performance.

## Potential limitations of the study

The present study has a few limitations to consider. The first limitation is that we assessed inflammatory cytokines once during the enrollment of MDD patients and HCs. Secondly, we should consider the effects of dietary supplementation, lifestyle, sleep patterns, and treatment on the investigated parameters in the present investigation. Also, the sample size, case-control nature, unadjusted associations, and modest predictive performance of ROC analysis limit our findings. Therefore, we recommend further studies with more samples and repeated cytokine measurements considering the above factors to produce better results. Despite the above constraints, this study has several strong points. According to our knowledge, it is the first-ever study to examine the association between serum resistin and G-CSF levels among MDD patients in Bangladesh. Also, the present study had a firm match in age and sex between the groups. We followed the same criteria for inclusion and exclusion of both cases and controls. Finally, we analyzed serum resistin and G-CSF levels under the same environment in MDD patients and HCs. Therefore, we hope that the present study findings would help to improve the recently accessible approaches for diagnosing and treating depression.

## Conclusion

Based on the present study findings, patients with severe depression had a considerable increase in serum resistin levels. Therefore, the elevated resistin levels in depression might be the result, not the cause of disease. Nevertheless, we did not find any such alterations in serum G-CSF levels between the groups. We propose serum resistin as a potential candidate marker of depression because of its increasing serum levels, connection with illness severity, and firm diagnostic performance. However, we recommend further studies with larger and more homogeneous samples based on these preliminary study findings.

## Supporting information

**S1 File.**
(XLSX)

## Acknowledgments

## Author Contributions

**Conceptualization:** Smaranika Rahman, Amena Alam Shanta, Sardar Mohammad Ashraful Islam, Md. Rabiul Islam.

**Data curation:** Smaranika Rahman, Amena Alam Shanta, Mohammad Shahriar, MMA Shalahuddin Qusar.

**Formal analysis:** Sohel Daria, Zabun Nahar, Mohammad Shahriar, Md. Rabiul Islam.

**Investigation:** Smaranika Rahman, Amena Alam Shanta, Sohel Daria, Md. Rabiul Islam.

**Methodology:** Sardar Mohammad Ashraful Islam, Mohiuddin Ahmed Bhuiyan, Md. Rabiul Islam.

**Project administration:** Mohammad Shahriar, Mohiuddin Ahmed Bhuiyan, Md. Rabiul Islam.

**Supervision:** Md. Rabiul Islam.

**Writing – original draft:** Smaranika Rahman, Sohel Daria.

**Writing – review & editing:** Zabun Nahar, MMA Shalahuddin Qusar, Md. Rabiul Islam.

## References

1. Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. *Nat Rev Dis Primers*. 2016; 2:16065. Published 2016 Sep 15. https://doi.org/10.1038/nrdp.2016.65 PMID: 27629598

2. American Psychiatric Association. Diagnostic statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Association, 2013.

3. Li Z, Ruan M, Chen J, Fang Y. Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications [published correction appears in Neurosci Bull. 2021 May 17;:]. *Neurosci Bull*. 2021; 37(6):863–880. https://doi.org/10.1007/s12264-021-00638-3 PMID: 33582959

4. World Health Organization. (2021). Depression. https://www.who.int/news-room/fact-sheets/detail/depression. Accessed on October 21, 2021.

5. Penninx BW, Nolen WA, Lamers F, et al. Two-year course of depressive and anxiety disorders: results from the Netherlands Study of Depression and Anxiety (NESDA). *J Affect Disord*. 2011; 133(1–2):76–85. https://doi.org/10.1016/j.jad.2011.03.027 PMID: 21496929

6. Malhi GS, Mann JJ. Depression. *Lancet*. 2018; 392(10161):2299–2312. https://doi.org/10.1016/S0140-6736(18)31948-2 PMID: 30396512

7. Hacimusalar Y, Eşel E. Suggested Biomarkers for Major Depressive Disorder. *Noro Psikiyatr Ars*. 2018; 55(3):280–290. Published 2018 May 28. PMID: 30224877

8. Das R, Emon MPZ, Chowdhury SF, Huque S, Zahan T, Islam MR. Evaluation of Serum Glial Cell Line-derived Neurotrophic Factor in Bangladeshi Major Depressive Disorder Patients. *Cureus*. 2019; 11(11): e6081. Published 2019 Nov 6. https://doi.org/10.7759/cureus.6081 PMID: 31853432

9. Islam MR, Islam MR, Ahmed I, et al. Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study. *SAGE Open Med*. 2018; 6:2050312118773953. Published 2018 May 9. https://doi.org/10.1177/2050312118773953 PMID: 29770218

10. Riya S, Sultana S, Daria S, et al. Evaluation of Serum Lysophosphatidic Acid and Lysophosphatidylcholine Levels in Major Depressive Disorder Patients. *Cureus*. 2020; 12(12):e12388. Published 2020 Dec 30. https://doi.org/10.7759/cureus.12388 PMID: 33542861

11. Islam MR, Ali S, Karmoker JR, et al. Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder. *BMC Psychiatry*. 2020; 20(1):333. Published 2020 Jun 24. https://doi.org/10.1186/s12888-020-02738-2 PMID: 32580709

12. Proma MA, Daria S, Nahar Z, Ashraful Islam SM, Bhuiyan MA, Islam MR. Monocyte chemoattractant protein-1 levels are associated with major depressive disorder [published online ahead of print, 2022 Jan 5]. *J Basic Clin Physiol Pharmacol*. 2022; https://doi.org/10.1515/jbcpp-2021-0132 PMID: 34983131

13. Daria S, Proma MA, Shahriar M, Islam SMA, Bhuiyan MA, Islam MR. Serum interferon-gamma level is associated with drug-naïve major depressive disorder. *SAGE Open Med*. 2020; 8:2050312120974169. Published 2020 Nov 20. https://doi.org/10.1177/2050312120974169 PMID: 33282305

14. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. *Neurosci Biobehav Rev*. 2005; 29(4–5):891–909. https://doi.org/10.1016/j.neubiorev.2005.03.023 PMID: 15885777

15. Milenkovic VM, Stanton EH, Nothdurfter C, Rupprecht R, Wetzel CH. The Role of Chemokines in the Pathophysiology of Major Depressive Disorder. *Int J Mol Sci*. 2019; 20(9):2283. Published 2019 May 9. https://doi.org/10.3390/ijms20092283 PMID: 31075818

16. Cowen PJ. Serotonin and depression: pathophysiological mechanism or marketing myth?. *Trends Pharmacol Sci*. 2008; 29(9):433–436. https://doi.org/10.1016/j.tips.2008.05.004 PMID: 18585794

17. Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology and treatment of mood disorders. *Biol Psychiatry*. 1999; 46(9):1219–1233. https://doi.org/10.1016/s0006-3223(99)00127-4 PMID: 10560027

18. Groves JO. Is it time to reassess the BDNF hypothesis of depression?. *Mol Psychiatry*. 2007; 12 (12):1079–1088. https://doi.org/10.1038/sj.mp.4002075 PMID: 17700574

19. Islam MR, Islam MR, Shalahuddin Qusar MMA, et al. Alterations of serum macro-minerals and trace elements are associated with major depressive disorder: a case-control study. *BMC Psychiatry*. 2018; 18(1):94. Published 2018 Apr 10. https://doi.org/10.1186/s12888-018-1685-z PMID: 29631563

20. Kopschina Feltes P, Doorduin J, Klein HC, et al. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. *J Psychopharmacol*. 2017; 31(9):1149–1165. https://doi.org/10.1177/0269881117711708 PMID: 28653857

21. Lehto SM, Huotari A, Niskanen L, et al. Serum adiponectin and resistin levels in major depressive disorder. *Acta Psychiatr Scand*. 2010; 121(3):209–215. https://doi.org/10.1111/j.1600-0447.2009.01463.x PMID: 19694629

22. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. *Nature*. 2001; 409 (6818):307–312. https://doi.org/10.1038/35053000 PMID: 11201732

23. Anjum S, Qusar MMAS, Shahriar M, Islam SMA, Bhuiyan MA, Islam MR. Altered serum interleukin-7 and interleukin-10 are associated with drug-free major depressive disorder. *Ther Adv Psychopharmacol*. 2020; 10:2045125320916655. Published 2020 Apr 28. https://doi.org/10.1177/2045125320916655 PMID: 32435448

24. Nishuty NL, Khandoker MMH, Karmoker JR, et al. Evaluation of Serum Interleukin-6 and C-reactive Protein Levels in Drug-naïve Major Depressive Disorder Patients. *Cureus*. 2019; 11(1):e3868. Published 2019 Jan 11. https://doi.org/10.7759/cureus.3868 PMID: 30899619

25. Das R, Emon MPZ, Shahriar M, et al. Higher levels of serum IL-1β and TNF-α are associated with an increased probability of major depressive disorder. *Psychiatry Res*. 2021; 295:113568. https://doi.org/10.1016/j.psychres.2020.113568 PMID: 33199026

26. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. *J Immunol*. 2005; 174(9):5789–5795. https://doi.org/10.4049/jimmunol.174.9.5789 PMID: 15843582

27. Brunetti L, Orlando G, Recinella L, Michelotto B, Ferrante C, Vacca M. Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus. *Eur J Pharmacol*. 2004; 493(1–3):41–44. https://doi.org/10.1016/j.ejphar.2004.04.020 PMID: 15189762

28. Papakostas GI, Shelton RC, Kinrys G, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. *Mol Psychiatry*. 2013; 18(3):332–339. https://doi.org/10.1038/mp.2011.166 PMID: 22158016

29. Kleinschnitz C, Schroeter M, Jander S, Stoll G. Induction of granulocyte colony-stimulating factor mRNA by focal cerebral ischemia and cortical spreading depression. *Brain Res Mol Brain Res*. 2004; 131(1–2):73–78. https://doi.org/10.1016/j.molbrainres.2004.08.011 PMID: 15530654

30. Schneider A, Krüger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. *J Clin Invest*. 2005; 115(8):2083–2098. https://doi.org/10.1172/JCI23559 PMID: 16007267

31. Eyles JL, Roberts AW, Metcalf D, Wicks IP. Granulocyte colony-stimulating factor and neutrophils—forgotten mediators of inflammatory disease. *Nat Clin Pract Rheumatol*. 2006; 2(9):500–510. https://doi.org/10.1038/ncprheum0291 PMID: 16951705

32. Ali S, Nahar Z, Rahman MR, Islam SMA, Bhuiyan MA, Islam MR. Serum insulin-like growth factor-1 and relaxin-3 are linked with major depressive disorder. *Asian J Psychiatr*. 2020; 53:102164. https://doi.org/10.1016/j.ajp.2020.102164 PMID: 32446216

33. Emon MPZ, Das R, Nishuty NL, Shalahuddin Qusar MMA, Bhuiyan MA, Islam MR. Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case-control study with or without antidepressant therapy. *BMC Res Notes*. 2020; 13(1):83. Published 2020 Feb 21. https://doi.org/10.1186/s13104-020-04952-3 PMID: 32085720

34. Schneider A, Kuhn HG, Schäbitz WR. A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. *Cell Cycle*. 2005; 4(12):1753–1757. https://doi.org/10.4161/cc.4.12.2213 PMID: 16258290

35. Meuer K, Pitzer C, Teismann P, et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. *J Neurochem*. 2006; 97(3):675–686. https://doi.org/10.1111/j.1471-4159.2006.03727.x PMID: 16573658

36. Weber-Hamann B, Kratzsch J, Kopf D, et al. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. *J Psychiatr Res*. 2007; 41(3–4):344–350. https://doi.org/10.1016/j.jpsychires.2006.01.002 PMID: 16497334

37. Becerril-Villanueva E, Pérez-Sánchez G, Alvarez-Herrera S, et al. Alterations in the Levels of Growth Factors in Adolescents with Major Depressive Disorder: A Longitudinal Study during the Treatment with Fluoxetine. *Mediators Inflamm*. 2019; 2019:9130868. Published 2019 Nov 19. https://doi.org/10.1155/2019/9130868 PMID: 31827384

38. Tunçel ÖK, Akbaş S, Bilgici B. Increased Ghrelin Levels and Unchanged Adipocytokine Levels in Major Depressive Disorder. *J Child Adolesc Psychopharmacol*. 2016; 26(8):733–739. https://doi.org/10.1089/cap.2015.0149 PMID: 26862938

39. Einvik G, Vistnes M, Hrubos-Strøm H, et al. Circulating cytokine concentrations are not associated with major depressive disorder in a community-based cohort. *Gen Hosp Psychiatry*. 2012; 34(3):262–267. https://doi.org/10.1016/j.genhosppsych.2012.01.017 PMID: 22401706

40. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. *Int J Biol Sci*. 2012; 8(9):1254–1266. https://doi.org/10.7150/ijbs.4679 PMID: 23136554

41. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006; 30(5):899–905. https://doi.org/10.1016/j.pnpbp.2006.01.029 PMID: 16616982

42. Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. *J Affect Disord*. 2007; 98(1–2):143–151. https://doi.org/10.1016/j.jad.2006.07.013 PMID: 16952400

43. Audet MC, Anisman H. Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. *Front Cell Neurosci*. 2013; 7:68. Published 2013 May 10. https://doi.org/10.3389/fncel.2013.00068 PMID: 23675319

44. Himmerich H, Binder EB, Künzel HE, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. *Biol Psychiatry*. 2006; 60(8):882–888. https://doi.org/10.1016/j.biopsych.2006.03.075 PMID: 16989778

45. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. *Prog Neurobiol*. 2008; 85(1):1–74. https://doi.org/10.1016/j.pneurobio.2008.01.004 PMID: 18346832

46. Gold PW. The organization of the stress system and its dysregulation in depressive illness. *Mol Psychiatry*. 2015; 20(1):32–47. https://doi.org/10.1038/mp.2014.163 PMID: 25486982

47. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006; 444(7121):860–867. https://doi.org/10.1038/nature05485 PMID: 17167474

48. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. *Biol Psychiatry*. 2010; 67(5):446–457. https://doi.org/10.1016/j.biopsych.2009.09.033 PMID: 20015486

49. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. *Biochem Biophys Res Commun*. 2005; 334(4):1092–1101. https://doi.org/10.1016/j.bbrc.2005.06.202 PMID: 16039994

50. De Kock M, Loix S, Lavand'homme P. Ketamine and peripheral inflammation. *CNS Neurosci Ther*. 2013; 19(6):403–410. https://doi.org/10.1111/cns.12104 PMID: 23574634

51. Machado-Vieira R, Gold PW, Luckenbaugh DA, et al. The role of adipokines in the rapid antidepressant effects of ketamine. *Mol Psychiatry*. 2017; 22(1):127–133. https://doi.org/10.1038/mp.2016.36 PMID: 27046644

52. Archer M, Niemelä O, Hämäläinen M, Moilanen E, Leinonen E, Kampman O. The effects of adiposity and alcohol use disorder on adipokines and biomarkers of inflammation in depressed patients. *Psychiatry Res*. 2018; 264:31–38. https://doi.org/10.1016/j.psychres.2018.03.073 PMID: 29626829

53. Jentsch MC, Burger H, Meddens MBM, et al. Gender Differences in Developing Biomarker-Based Major Depressive Disorder Diagnostics. *Int J Mol Sci*. 2020; 21(9):3039. Published 2020 Apr 25. https://doi.org/10.3390/ijms21093039 PMID: 32344909

54. Stewart JW, McGrath PJ, Quitkin FM, Klein DF. Atypical depression: current status and relevance to melancholia. *Acta Psychiatr Scand Suppl*. 2007;(433):58–71. https://doi.org/10.1111/j.1600-0447.2007.00964.x PMID: 17280572

55. Pan A, Ye X, Franco OH, et al. The association of depressive symptoms with inflammatory factors and adipokines in middle-aged and older Chinese. *PLoS One*. 2008; 3(1):e1392. Published 2008 Jan 2. https://doi.org/10.1371/journal.pone.0001392 PMID: 18167551

56. Lehto SM, Tolmunen T, Joensuu M, et al. Changes in midbrain serotonin transporter availability in atypically depressed subjects after one year of psychotherapy. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008; 32(1):229–237. https://doi.org/10.1016/j.pnpbp.2007.08.013 PMID: 17884269

57. Fink M, Taylor MA. The medical evidence-based model for psychiatric syndromes: return to a classical paradigm. *Acta Psychiatr Scand*. 2008; 117(2):81–84. https://doi.org/10.1111/j.1600-0447.2007.01146.x PMID: 18199152

58. Smith RS. The macrophage theory of depression [published correction appears in Med Hypotheses 1991 Oct;36(2):178]. *Med Hypotheses*. 1991; 35(4):298–306. https://doi.org/10.1016/0306-9877(91)90272-z PMID: 1943879

59. Lee ST, Chu K, Jung KH, et al. Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. *Brain Res*. 2005; 1058(1–2):120–128. https://doi.org/10.1016/j.brainres.2005.07.076 PMID: 16150422

60. Metcalf D, Begley CG, Johnson GR, et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. *Blood*. 1986; 67(1):37–45. PMID: 3484428

61. Lehto SM, Huotari A, Niskanen L, et al. Serum IL-7 and G-CSF in major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010; 34(6):846–851. https://doi.org/10.1016/j.pnpbp.2010.03.033 PMID: 20382196

62. Galván ST, Flores-López M, Romero-Sanchiz P, et al. Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder. *Sci Rep*. 2021; 11(1):13629. Published 2021 Jul 1. https://doi.org/10.1038/s41598-021-93075-1 PMID: 34211033

63. Dahl J, Ormstad H, Aass HC, Sandvik L, Malt UF, Andreassen OA. Recovery from major depressive disorder episode after non-pharmacological treatment is associated with normalized cytokine levels. *Acta Psychiatr Scand*. 2016; 134(1):40–47. https://doi.org/10.1111/acps.12576 PMID: 27028967

64. Royall DR, Al-Rubaye S, Bishnoi R, Palmer RF. Serum proteins mediate depression's association with dementia. *PLoS One*. 2017; 12(6):e0175790. https://doi.org/10.1371/journal.pone.0175790 PMID: 28594820

65. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science*. 2003; 301(5631):386–389. https://doi.org/10.1126/science.1083968 PMID: 12869766